ClinicalTrials.gg
RecruitingNCT07485803Updated Jun 22, 2026

Methadone in the Management of Post-Operative Pain in Total Knee Replacement

A Phase 4 interventional study of Methadone in Total Knee Arthroplasty, sponsored by AdventHealth. Recruiting at 1 site in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by AdventHealth · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Study summary

The goal of this study is to determine whether one dose of IV methadone given right before surgery will help patients' pain management after a total knee replacement and reduce the amount of pain medications taken in the weeks after surgery.

02

Conditions studied

  • Total Knee Arthroplasty

Keywords

  • pain management
  • TKA
  • methadone
03

In context

Lead sponsor

AdventHealth is the lead sponsor of 114 studies on the registry; 23 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated from
  2. Stated willingness to comply with all study procedures and availability to attend all required visits for the duration of the study.
  3. Age 21- 75
  4. Unilateral total knee arthroplasty at Colorado Joint Replacement
  5. All individuals will be screened for drug use (opioid use, illicit drug use) at their preoperative appointment
  6. For females of : use of highly effective for at least 1 month prior to screening and agreement to use such a method during study participation.

Exclusion criteria

Exclusion Criteria:

  1. Narcotic use in the past 6 weeks
  2. Current or previous history of drug and alcohol abuse
  3. Tobacco use in the previous 90 days
  4. Treatment with another drug
  5. Patients that cannot receive spinal anesthesia
  6. Patients that cannot receive the standardized multimodal pain medications (i.e. Tylenol, gabapentin and meloxicam)'
  7. Patients that are not able to go home after leaving the hospital and require a short-term rehabilitation facility
  8. Obstructive sleep apnea
  9. Morbid obesity ( >40)
  10. Patients with liver disease.
  11. Significant kidney disease - stage 3 CKD or greater
  12. Pregnant or nursing females
  13. Baseline >480
  14. severe (GOLD 3 or 4)
  15. home oxygen requirement
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    Methadone

    Patient will receive one perioperative dose of IV methadone prior to their surgical procedure in addition to standard of care medications.

    Drug: Methadone

  • No intervention
    No medication

    Patient will receive only the standard of care medications for their procedure.

Interventions

  • Subjects randomized to receive methadone will be given one dose of methadone 0.15mg/kg intravenously dosed based on ideal body weight administered by the anesthesia team prior to surgical incision

06

What researchers measure

Primary outcomes

  1. Opioid use for 48 hours post-operatively

    Opioid use will be calculated using morphine milligram equivalents (MME). Patients will keep a log to track opioid consumption.

    Time frame: 48 hours after TKA procedure

Secondary outcomes

  1. Defense and Veterans Pain Scale

    Using the Defense and Veterans Pain Scale, patients will rate their pain ranging from 0 (no pain) to 10 (severe pain)

    Time frame: 2 weeks after TKA procedure

  2. Opioid-Related Symptom Distress Scale (ORSDS)

    4-point scale that evaluates 12 symptoms in 3 symptom categories including frequency, severity, and bothersomeness. The ORSDS may be used to calculate a symptom-specific score, which is the average of the 3 symptom distress dimensions and range from 0 to 4. The composite ORSDS score is the mean of all 12 symptom-specific scores. Composite ORSDS scores range from 0 to 4.

    Time frame: At baseline and 2 weeks after TKA procedure

  3. Pittsburgh Sleep Quality Index

    Patients will complete survey to monitor sleeping habits

    Time frame: At baseline and 2 weeks after TKA procedure

  4. Total opioid usage over 2 weeks post-operatively

    Opioid use will be calculated using morphine milligram equivalents (MME). Patients will keep a log to track opioid consumption.

    Time frame: 2 weeks after TKA procedure

  5. Knee Society Score

    This survey includes alignment, instability, joint range of motion, and symptoms. A higher score indicates good alignment, range of motion, and minimal symptoms of pain. A lower score indicates poor knee alignment, potential issues in range of motion, and the likely experience of symptoms of pain.

    Time frame: At baseline

  6. KOOS-12 Knee Survey

    This survey is used to evaluate knee pain, function and quality of life. The total score ranges from 0 to 100, where higher scores indicate better outcomes.

    Time frame: At baseline

  7. Veterans Rand 12-Item Health Survey (VR-12)

    This survey assesses overall health-related quality of life across physical and mental domains. It generates two summary scores-Physical Component Summary (PCS) and Mental Component Summary (MCS)-to provide a standardized evaluation of a patient's functional health and well-being.

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kharasch ED. Intraoperative methadone: rediscovery, reappraisal, and reinvigoration? Anesth Analg. 2011 Jan;112(1):13-6. doi: 10.1213/ANE.0b013e3181fec9a3. No abstract available. PubMed 21173206 ↗
  • Komen H, Brunt LM, Deych E, Blood J, Kharasch ED. Intraoperative Methadone in Same-Day Ambulatory Surgery: A Randomized, Double-Blinded, Dose-Finding Pilot Study. Anesth Analg. 2019 Apr;128(4):802-810. doi: 10.1213/ANE.0000000000003464. PubMed 29847382 ↗
  • Friesgaard KD, Brix LD, Kristensen CB, Rian O, Nikolajsen L. Clinical effectiveness and safety of intraoperative methadone in patients undergoing laparoscopic hysterectomy: a randomised, blinded clinical trial. BJA Open. 2023 Aug 5;7:100219. doi: 10.1016/j.bjao.2023.100219. eCollection 2023 Sep. PubMed 37638083 ↗
  • Morris BJ, Mir HR. The opioid epidemic: impact on orthopaedic surgery. J Am Acad Orthop Surg. 2015 May;23(5):267-71. doi: 10.5435/JAAOS-D-14-00163. PubMed 25911660 ↗
  • Menendez ME, Ring D, Bateman BT. Preoperative Opioid Misuse is Associated With Increased Morbidity and Mortality After Elective Orthopaedic Surgery. Clin Orthop Relat Res. 2015 Jul;473(7):2402-12. doi: 10.1007/s11999-015-4173-5. Epub 2015 Feb 19. PubMed 25694266 ↗
  • Cancienne JM, Patel KJ, Browne JA, Werner BC. Narcotic Use and Total Knee Arthroplasty. J Arthroplasty. 2018 Jan;33(1):113-118. doi: 10.1016/j.arth.2017.08.006. Epub 2017 Aug 17. PubMed 28887020 ↗
  • Li WT, Bell KL, Yayac M, Barmann JA, Star AM, Austin MS. A Postdischarge Multimodal Pain Management Cocktail Following Total Knee Arthroplasty Reduces Opioid Consumption in the 30-Day Postoperative Period: A Group-Randomized Trial. J Arthroplasty. 2021 Jan;36(1):164-172.e2. doi: 10.1016/j.arth.2020.07.060. Epub 2020 Jul 30. PubMed 33036845 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Apr 2028, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 20, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Jun 2028
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07485803
Lead sponsor
AdventHealth
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Jun 1, 2026
Primary completion
Apr 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jun 22, 2026

Study contacts

Makenna Hemmerle
Contact
makenna.hemmerle@adventhealth.com
303-260-2951

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion